<DOC>
	<DOC>NCT00771329</DOC>
	<brief_summary>Phase I study designed to determine the safety and tolerability of a single dose of BIIB023 administered intravenously versus placebo to subjects with RA.</brief_summary>
	<brief_title>BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Diagnosis of adult onset RA (functional class IIII) for at least 6 months Must have been treated with and be tolerating Methotrexate (525 mg/week) for 3 months, at a stable dose for at least 4 weeks Must have at least 4 swollen and tender joints due to rheumatoid arthritis History of recurrent infections requiring antibiotic treatment within 12 months Serious local infection or systemic infection within 3 months Suffering from rheumatic or autoimmune disease other than RA History of cancer, heart failure, kidney disease, liver disease, HIV infection, tuberculosis or other serious illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>